Airway Epithelial SARS-CoV-2 Infectious and Repair Responses: Relationships to Age, Sex, and Post-COVID Pulmonary Syndromes

Hong Dang[1*], Caitlin E. Edwards[2*], Takafumi Kato[1,3*], Boris Reidel[1], Rita M. Meganck[4], Charles R. Esther, Jr[1]., Camille Ehre[1], M. Leslie Fulcher[1], Alexis B. Bailey[2], Michelle R. Cooley[5], Yu Mikami[1,6], Takanori Asakura[7], Padraig E. Hawkins[1], Minako Saito[1], Jeffrey L. Myers[8], Kristine Konopka[8], Firoozeh V Gerayeli[9], Hye Yun Park[9], Don D. Sin[9,10], Alessandra Livraghi-Butrico[1], Kenichi Okuda[1], Raymond J. Pickles[1,11], Sabra Klein[12], Scott H. Randell[1], Wanda K. O'Neal[1], Ralph S. Baric[2], Richard C. Boucher[1]

[1]Marsico Lung Institute/Cystic Fibrosis Research Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC

[2]Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC

[3]NHO Tokyo National Hospital, Tokyo, Japan

[4]Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.

[5]The University of Chicago Medical Center

[6]Department of Respiratory Medicine, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan, 113-8655

[7]Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

[8]Department of Pathology, University of Michigan Medical School, Ann Arbor, MI

[9]Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, Canada

[10]Division of Respiratory Medicine, Department of Medicine, University of British Columbia,

Vancouver, BC, Canada

[11]Department of Microbiology and Immunology, University of North Carolina at Chapel Hill,

Chapel Hill, NC

[12]Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD

Corresponding Author:

Richard C. Boucher

7008 Marsico Hall

Chapel Hill, NC 27599-7248

919-966-7064

richard_boucher@med.unc.edu)

*contributed equally to this manuscript

Conflict of Interest Statement: Drs. Randell and O'Neal serve as grant reviewers for the Cystic

Fibrosis Foundation. Dr. Baric is a member of the advisory boards for VaxArt, Takeda and

Invivyd, has consulted for Gilead, and has collaborative projects with Gilead, J&J, and Hillevax,

focused on unrelated projects.

Abstract

The long-term pulmonary sequelae of SARS-CoV-2 respiratory infections reflect infection

severity, innate and adaptive immunity, and respiratory epithelial repair. This study investigated

the acute and reparative responses as a function of age and sex in primary human bronchial

epithelial (HBE) cultures utilizing a 14-day SARS-CoV-2 infection protocol. SARS-CoV-2

infection peaked at 3 days post-infection (dpi) with an ~ 2 log titer suppression at 14 dpi. SARS-

CoV-2 infection induced interferon, interferon-induced gene, and cell damage responses. No

age- or sex-dependent effects on SARS-CoV-2 infection were detected. Airway epithelia

repaired to an abnormal mucus metaplastic/inflammatory state that reflected potentially

beneficial and adverse consequences at 14 dpi. Repair processes were infection severity-

dependent, not sex-dependent, and were more robust in young donor cultures. Analyses of long-

COVID subjects with persistent pulmonary fibrosis or persistent bronchitic airway diseases

exhibited expression of HBE 14 dpi failed repair gene signatures, including ISG gene signatures.

Human airway epithelial repair post-SARS-CoV-2 is prolonged and incomplete *in vitro* over 14

days, and persistently abnormal repair may contribute to phenotypes of people with long-COVID

pulmonary syndrome.

Introduction

The respiratory outcomes following SARS-CoV-2 infections reflect multiple genetic and environmental variables (1-3). The severity of the lower airway infection, coupled with virus-modified epithelial repair programs and pre-existing epithelial health, are major variables predicting the severity of SARS-CoV-2 outcomes (4-8). Age and sex have also been related to SARS-CoV-2 disease severity (9-13). Children of both sexes are reported to exhibit less severe disease outcomes than adults (14, 15). Within the adult population, SARS-CoV-2 infection in older males generally is associated with more persistent disease (16). However, it has been difficult to attribute the relative risk of persistent disease in older males to differences in intrinsic epithelial infectivity/innate defense, age of the immune system, and/or comorbidities (17-20).

The first goal of this study was designed to identify potential contributions of human bronchial epithelia (HBE) to the acute and chronic (persistent COVID) outcomes of SARS-CoV-2 respiratory infections *in vitro* as a function of sex and age. Well-differentiated HBE cultures derived from sex-matched donors comprising a wide spectrum of age, including children aged 4 mo-8 yrs, young adults (20-30 yrs; referred to as mature), and the elderly (> 69 yrs), were studied over a prolonged post-SARS-CoV-2 inoculation (14 day interval) to capture potential age- and sex-dependent differences in: 1) the kinetics, magnitude and clearance of the initial infection; 2) the response/effects on the respiratory epithelium at peak viral infection; 3) how respiratory epithelia manifest SARS-CoV-2 infection post the peak infection period; and 4) how respiratory epithelia adapt and repair after peak epithelial infection/damage. A second goal of this study investigated whether *in vitro* d14-derived airway epithelial repair gene expression profiles persisted in specimens/data from subjects with prolonged (many months) failed epithelial repair

manifested in fibrotic and "bronchitic" sequelae of SARS-CoV-2 infection.

Results

A. Global kinetics of virus infection

Kinetics of Viral Titers

Evidence of productive viral infection was present in 23 of the 24 experimental cultures of

human bronchial epithelial (HBE) cells as assayed by live virus titers outlined in Protocol 1

(**Figure 1A and Supplemental Figure 1A;** note, the absence of infection of the one culture was

deemed to reflect technical reasons, and it was removed from all analyses; see **Supplemental**

Table 1). Measurable increases in virus titer were observed at 1 day post-infection (dpi), and

titers peaked in 22/23 HBE donors at 3 dpi, the rate increasing with an average slope of 1.59 log

titer/day (**Figure 1A and Supplemental Figure 2Ai**). Titers were reduced by 7 dpi and either

leveled off or continued to decrease by 14 dpi, with 9 of 23 cultures exhibiting no measurable

live virus titer at 14 dpi (**Figure 1A**). Consequently, throughout this report, cultures that exhibit a

loss of live virus by 14 dpi are termed "suppressors" and those cultures with measurable titers

still present at 14 dpi are termed "non-suppressors". The slopes describing the decline of

infection over the 3-14 dpi interval described a viral clearance rate ~5 times slower than the rate

of virus production between 1-3 dpi (average slope of -0.3 log titer/day; **Supplemental Figure**

2Aii). The rate of decrease was faster (by -0.23 log titer/day) in suppressors vs. non-suppressor

HBE donors (**Supplemental Figure 2Aiii**). Collectively, the kinetics and magnitude of virus

growth observed *in vitro* resembled those of previous *in vitro* studies (21, 22) and *in vivo*

challenge studies of young healthy subjects (23).

Kinetics of Total Intracellular Viral Transcripts

In addition to live virus titer determinations, intracellular viral RNA transcripts were measured at

time of culture collection by bulk RNA sequencing (bulk RNAseq). The nucleocapsid (N)

transcript was selected as an indicator of global SARS-CoV-2 viral mRNA and genome

production (see Supplemental methods for explanation) (24). N transcripts, expressed as

transcripts/million reads (TPM), were detectable by 1 dpi, increased to peak values at 3 dpi, and

then subsequently declined through 14 dpi (**Figure 1B**). The rate of acquisition of viral TPM was

similar to that measured by titer (slope 1.12 vs. 1.59, respectively; **Supplemental Figure 2, Bi**

vs. Ai). In contrast to the loss of detectable live virus titer in suppressors, a complete loss of

intracellular viral transcripts was not observed at 14 dpi in any HBE culture (compare **Figure 1,**

A and B, and Supplemental Figure 2, Aii and Bii, Aiii and Biii). These data demonstrate the

persistence of intracellular viral RNA in all cultures, despite the absence of measurable live virus

in 39% of the cultures.

Kinetics of HBE Apical Surface Viral Proteome

Proteomics analyses identified SARS-CoV-2 viral proteins present in the apical washes sampled

across all dpi (**Figure 1C and Supplemental Figure 2C**). Nucleocapsid (NCAP) was at the

borderline of detection at 1 dpi, peaked at 3 dpi, and waned approximately 10-fold by 14 dpi

(**Figure 1C and Supplemental Figure 2C, i and ii**).While we focused on NCAP protein as

representative, similar patterns were observed for the spike protein, and, despite ~10-fold less

protein levels, for ORF8 (also called NS8) and ORF9B (**Supplemental Figure 2D**). As with

intracellular viral TPM, extracellular viral protein was still detectable at 14 dpi in suppressor

cultures (**Supplemental Figure 2Ciii**).

Correlations between Viral Titers, Intracellular TPM, and Apical Viral Proteins

Globally, viral titers were correlated with both SARS-CoV-2 RNA expression (using N mRNA

as the representative transcript; **Figure 1Di**) and protein (using NCAP as the representative

SARS-CoV-2 protein; **Figure 1Dii**). The correlation was strongest between SARS-CoV-2 RNA

and NCAP protein (**Figure 1Diii**). The complete suppression of SARS-CoV-2 titers in cultures

that continued to exhibit measurable SARS-CoV-2 gene expression and extracellular protein

reduced the overall correlations with live virus titer. Comparisons of viral titer with SARS-CoV-

2 TPM or extracellular viral protein with time revealed a reduction in both viral:TPM or viral:N

protein from 1 dpi to 3 dpi, followed by a linear increase in ratios by 7 dpi, which leveled off in

non-suppressors at 14 dpi (**Figure 1E**). Overall, these findings suggest two conclusions: 1)

SARS-CoV-2 virus is maximally efficient at producing infectious virions in HBE cultures at 3

dpi, waning thereafter; and 2) a period of viral RNA persistence and protein shedding onto apical

HBE surfaces in the absence of detectable infectious virions can occur late (*e.g.*, 14 dpi) in a

SARS-CoV-2 infection, a finding of relevance to clinical antigen testing as a measure of

infectious virus (23, 25).

SARS-CoV-2 Mutation Analyses

We tested the hypothesis that the mutation load in the SARS-CoV-2 genome would lead to the

ability of the virus to persist in human airway epithelial cultures. Mutations acquired by the

SARS-CoV-2 virus over 14 dpi were identified for each culture. Both coding and non-coding

mutations were observed throughout viral RNA at 14 dpi (**Supplemental Figure 2Ei**). There

were no differences in mutation load amongst cultures that suppressed or did not suppress viral

titers (**Supplemental Figure 2Eii**). Thus, we conclude that HBE responses, not viral mutations,

were the major drivers of viral kinetics in our system.

B. Variables that affect HBE SARS-CoV-2 Infectivity

The basal state of airway epithelia is a major contributor to viral infectivity (26). Accordingly,

we analyzed expression in 1 dpi mock exposed cultures for variables reportedly related to SARS-

CoV-2 viral infectivity referenced to SARS-CoV-2 titers at 3 dpi. As expected, mRNA

expression levels at 1 dpi in mock (basal) cultures for the proteins mediating SARS-CoV-2

binding/entry, *e.g.*, ACE2, TMPRSS2, and TMEM106B (27), were positively and significantly

correlated with SARS-CoV-2 titers at 3 dpi (**Figure 2A-C**). Multiple studies have also focused

on the relationships between ciliated cells and infection of airway epithelia by SARS-CoV-2 (22,

28-31). Two indices of HBE culture ciliation were utilized to examine relationships to infection:

1) The cilia-covered apical surface of the epithelium per basement membrane length was

morphologically scored in mock cultures paired with infected cultures; and 2) a gene set based

on cell ciliation was constructed and used to analyze mock 1 dpi cultures. The two metrics were

correlated (r^2=0.49; **Supplemental Figure 3A**), and positive but non-significant correlations

were observed between both metrics and viral titer 3 dpi (**Figure 2D and Supplemental Figure**

3B). The relationships observed between viral titers with ACE2, TMPRSS2, and ciliation were

generally similar when correlated to viral RNA (**Supplemental Figure 3C-E**).

We next evaluated whether baseline interferon expression, potentially reflecting a preexisting

inflammatory state, would associate with viral titer at 3 dpi (26, 32-34). The baseline expression

of a 13 gene index set of Type I interferon (IFN) stimulated genes previously reported, and with

mean expression >50 TPM from mock infection samples, was utilized for this analysis (35). No

relationships were detected between the basal expression of these genes and SARS-CoV-2

infection as indexed by viral titer or viral N gene TPM at 3 dpi (**Supplemental Figure 3F**). In

addition, an index of genes reported to govern viral entry/infectivity was developed and tested

for relationships to infectivity (36). A significant correlation was observed between basal

expression of these genes and SARS-CoV-2 titer and viral N at 3 dpi (**Figure 2E and**

Supplemental Figure 3G). Curiously, many of these genes were also upregulated by virus in the

bulk RNAseq data (**Supplemental Figure 3H**). Finally, PLSCR1 has been reported to inhibit

SARS-CoV-2 entry/replication (37). In contrast to predictions, a positive correlation was

observed between mock/basal PLSCR1 expression and SARS-CoV-2 titer at 3 dpi (**Figure 2F**).

C. IFN and ISG Response Kinetics

The interferon pathway is of critical importance in host responses to infection (26, 38-41). After

SARS-CoV-2 infection, HBE cultures robustly increased expression of *IFNL1*, *IFNL2*, *IFNL3*

and *IFNB1* (**Figure 3A**), with little expression or induction of *IFNL4, IFNA1, IFNG* or *IFNE*

(**Supplemental Figure 4A**). The kinetics of the expressed IFN genes all followed a similar

pattern, *i.e.*, little induction was detected at 1 dpi, robust induction noted at 3 dpi, whereas

induction waned rapidly by 7 and 14 dpi (**Figure 3A**).

Using a previously defined Type I INF-stimulated gene (ISG) set, a robust ISG response was

observed that peaked at 3 dpi and waned thereafter (**Figure 3B**) (35). The ISGs remained

elevated over baseline in most cultures at 14 dpi. Notably, a small number of ISGs exhibited a

more persistent response, defined as greater fold changes over mock samples at 14 than 3 dpi.

These genes included *IFI27, BST2, IFI6*, and *IFI44L* (**Supplemental Figure 4B**). In contrast to

RNA data, a smaller number of ISGs were detected by proteomics of luminal secretions (**Figure**

3C). ISG proteins markedly increased in secretions at 3 dpi above 1 dpi levels, including

CXCL10, LAP3, and SAMHD1, whereas the majority of ISG proteins in luminal secretions

peaked at 7-14 dpi. This difference may represent a lag between ISG gene induction and protein

secretion and/or ISG release post-cell death.

To relate SARS-CoV-2 infection to IFN and ISG responses over the infection interval, we

plotted SARS-CoV-2 infection, IFN responses, and RNA-measured ISG responses as a function

of the percent peak mean response vs. time (**Figure 3D**). Compared to both viral titer and viral N

TPM (**Figure 3D, i and ii**), the intracellular IFN RNA responses peaked at 3 dpi, waned over 7-

14 dpi, and did not differ between viral titer suppressor vs. non-suppressor groups (**Figure**

3Diii). In comparison to IFN responses, the ISG responses exhibited similar kinetics at 3 dpi but

were persistently expressed over the experimental interval (**Figure 3Div**), again with no

significant differences between suppressor and non-suppressor cultures. These data are generally

consistent with the associations predicted for a SARS-CoV-2-induced IFN and subsequent ISG

response (41). Notably, the patterns of IFN and ISG responses were not directly related to the

detection of live infectious virus (titer) at 14 dpi as revealed by suppressor vs. non-suppressor

comparison. Thus, the persistent IFN and ISG responses could be driven by the continued

presence of intracellular viral RNA transcripts and/or epigenetic changes that prevent a quick

loss of IFN/ISG gene expression during a viral event.

D. Global Transcriptomic Responses to SARS-CoV-2 Virus Infection 1-14 dpi.

In addition to ISG responses, bulk RNAseq was used to catalogue other global epithelial

responses to SARS-CoV-2 infection with time. Principal component analyses (PCA) and

differential gene expression (DEG) analyses of the integrated HBE RNA expression dataset

demonstrated that virus treatment was a strong overall driver of major differences in HBE cell

gene expression post-infection at all timepoints measured (**Figure 4A-C**). SARS-CoV-2

infection induced significant up and down regulation of in gene expression, with different DEG

noted across time post-infection, especially after 1 dpi (**Figure 4, C and D, and Supplemental**

Figure 5A). A combined heatmap of differentially regulated genes comparing SARS-CoV-2-

infected vs. mock HBE cultures across all times and treatment groups provides visualization of

the major shifts driven by time (**Supplemental Figure 5B**).

As predicted from the large number of DEGs and the clustering data, pathway analyses identified

highly significant pathway signatures driven by SARS-CoV-2 infection (**Supplemental Table**

2). A simplified heatmap of pathway responses demonstrated several key processes significantly

altered at times from 1 to 14 dpi (**Figure 4E**). These pathways included interferon and cytokine

signaling, mitotic signaling, NOTCH/Wnt signaling, and several stress pathways, including

senescence and programmed cell death. Notably, no relationships were detected between IFs,

ISGs, or genes associated with infectious viral production (*e.g.*, viperin, tetherin) and suppressor

vs. non-suppressor status (data not shown). Down-regulated pathways at 7 dpi related to

translation could reflect the activity of ISGs to control viral infection.

We also asked if genes identified in GWAS studies (42) were involved in epithelial responses to

SARS-CoV-2 in HBE. Interestingly, many of the genes identified in GWAS studies associated

with Covid-19 susceptibility and/or severity were expressed in airway epithelia, and as a group,

they were responsive to virus infection after 3 dpi (**Supplemental Figure 5C**). These results

suggest that the epithelial response, not just immune cell responses, to virus infection could play

key roles in the presentation of Covid-19 in the clinic.

E. Acute 1-3 dpi Cell Biologic Responses to Peak SARS-CoV-2 Infection of HBE Cultures

We next sought to characterize the effects of SARS-CoV-2 infection on HBEs at peak titers (3

dpi) using a combination of morphologic, cell biologic, proteomics, mass spectroscopy, and bulk

RNAseq approaches. Previous studies have shown that the SARS-CoV-2 1-3 dpi interval is

associated with a high degree of shedding of infected and apoptotic/necrotic dead ciliated cells

(28). Cell death is also associated with release of cellular danger associated signals (DAMPs)

(30). Consistent with these data, an increased incidence of cell death was observed at 3 dpi as

indexed by the TUNEL assay (**Figure 5Ai and Supplemental Figure 6A**) and measures of

ZBP1 RNA (**Supplemental Figure 6B**) (43). Mass spectrometric analyses of luminal secretions

revealed increased LDHB release over the 3-7 dpi interval (**Figure 5Aii**) and increased HMGB1

release that peaked at 3 dpi (44) (**Figure 5Aiii**).

Airway epithelia also manifest a complex balance of small molecule-mediated mechanisms that

can promote or dampen inflammatory responses to injury. We have previously reported that

release of ATP as a DAMP is coincident with peak SARS-CoV-2 infections of HBE cells and

serves as a second signal to promote inflammasome activation in locally resident airway

macrophages (15). ATP is metabolized on airways surfaces by a series of extracellular metabolic

enzymes that convert ATP to intermediate metabolites (AMP, adenosine, inosine, hypoxanthine,

xanthine) with a final product of uric acid (UAC) (**Supplemental Figure 6C**). Expression of

many genes within this pathway were altered in the 3-7 dpi interval (**Supplemental Figure 6Ci**),

and mass spectrometric analysis of HBE apical secretions revealed increases in ATP metabolites

and uric acid at day 3 dpi (**Figure 5Bi-ii and Supplemental Figure 6Cii**), consistent with acute

ATP release serving as a pro-inflammatory/pro-inflammasome-activating moiety.

Another small molecule pathway known to be regulated in relationship to viral infection is the

methionine salvage pathway, in which the anti-inflammatory molecule methylthioadenosine

(MTA) is converted back to methionine (45). We observed an increase in apical concentrations

of MTA with a corresponding decrease in adenine (a product of MTA hydrolysis) at day 3 dpi

with no significant change in methionine levels (**Figure 5Biii-iv**) in parallel with decreased

expression of genes involved in the methionine salvage pathway (**Supplemental Figure 6D**).

These findings suggest the virus-induced downregulation of this salvage pathway with

augmented MTA anti-inflammatory activity early in the post infection interval.

Bulk RNAseq analyses revealed additional global alterations in fundamental HBE cell biologic

functions associated with peak SARS-CoV-2 infection. For example, a large fraction of the

nuclear-encoded mitochondrial genes were suppressed at 3 dpi but were overexpressed later

(**Figure 5C**). A strong upregulation at 3 dpi of DNA methylation/chromatin remodeling

signatures, *e.g.*, histone acetylation, was also observed which was maintained but declined over

14 dpi (**Figure 5D**).

Inflammatory/cytokine genes included in the "cytokine-cytokine receptor interaction" KEGG

pathway (hsa04060) were also globally elevated by virus at 3 dpi and after (**Figure 5E**).

However, the genes in this pathway appeared to cluster in two broad categories, one that peaked

at 7 dpi and remained elevated and a second group that that were non-responsive to virus

infection.

F. Adaptive, Maladaptive, and Reparative 3-14 dpi HBE Responses Post-Peak Viral SARS-

CoV-2 Infection

In many airway disease states following injury, *e.g.*, virus infection, the epithelium remodels

from the ciliated cell-dominated state to one characterized by mucus cell metaplasia (46).

Accordingly, we characterized the cellular morphologies of HBE cultures over the post-SARS-

CoV-2 peak infectious interval to test for repair/metaplastic processes post-SARS-CoV-2

infection. While ciliated cell loss was not evident at 3 dpi, an ~ 50% reduction of ciliated cell

numbers in infected cultures was observed at 14 dpi compared to mock (**Figure 6Ai**). Further,

the ratio of ciliated cell gene expression to ciliated cell numbers differed between infected and

mock cultures, with lower numbers of ciliated cells present for equivalent ciliated cell gene

expression in the infected group (**Figure 6Aii**). A comprehensive heatmap of ciliated cell gene

expression shows high variability, but a general reduction in mature multi-ciliated cell gene

expression after virus infection was observed at 3 and 7 dpi (**Supplemental Figure 7A**). Newly

differentiating ciliated cells transition from suprabasal/secretory cells through a deuterosomal

cell state (47). Interestingly, despite an overall decrease in ciliated cells and ciliated cell gene

expression, HBE cultures post-virus exhibited an increase in deuterosomal cell gene expression,

especially at 7 dpi (**Figure 6Aiii and Supplemental Figure 7B**). These data suggest that there is

a delay/failure of the deuterosomal cell population to regenerate a mature multiciliated

epithelium.

Consistent with our previous report, AB-PAS staining demonstrated an increase in AB-PAS-

positive cells by 14 dpi, consistent with mucus cell metaplasia, in SARS-CoV-2-infected cultures

(**Supplemental Figure 7C** (46). Mucus cell metaplasia can reflect metaplasia of pre-existing

secretory cells into a mucus ("goblet") cell phenotype and/or commitment of regenerative cells,

e.g., basal cells/suprabasal cells, into this cellular phenotype. Pertinent to these possibilities,

analyses of bulk RNAseq data revealed 1) an increase in basal cell and cell cycling genes (*e.g.*,

TP53 cell cycle pathway) in the interval post-peak infection, consistent with the notion that at

least part of the mucus cell metaplasia represented a cell proliferative/replacement response to

viral injury (**Figure 6B**); and 2) strong upregulation of EGFR signaling pathways that are likely

to mediate a component of the mucus metaplastic response to SARS-CoV-2 (46, 48, 49) (**Figure**

6C).

The post-infection 7-14 dpi HBE epithelium also exhibited other indices of chronic

injury/damage. For example, upregulation of genes associated with cellular senescence at 3, 7

and 14 dpi was observed (**Supplemental Figure 7D**). Epithelial cells in the senescent state may

contribute to the pro-inflammatory pathways that persisted over the 14-d interval post-infection

(**Figure 5E**) (50). Adrenomedullin, which recruits ILC2s into airway walls and promotes Type 2

responses, was also upregulated in the post 3 dpi state (**Supplemental Figure 7E**) (51). In

parallel, there was a reduction in mitochondrial-encoded gene expression over the 7-14 dpi

interval, supporting the concept that virus infections lead to defects in cellular bioenergetics

(**Figure 6D**). The downregulation of mitochondrial-encoded genes contrasted to increased

expression of nuclear-encoded mitochondrial genes shown in **Figure 5C**. Thus, the post-SARS-

CoV-2-infected epithelium exhibits a complex spectrum of repair, adaptation, and dysfunction.

G. Host Defense Responses to SARS-CoV-2-Infected Airway Epithelia

In the context of injury, airway epithelia need to maintain elements of host defense. A major host

airway defense mechanism is the mucociliary transport system (52). This system is in part

dependent on ciliated cell numbers, which are reduced (see **Figure 6A**), predicting a degradation

of the efficiency of this system (53). However, mucociliary transport is also governed by the

mass of mucins on airway surfaces and the hydration of secreted mucins mediated by airway

epithelial ion transport systems (52, 54). An increase in the dominant host defense airway

epithelial secreted mucin, MUC5B, was observed by RNA, proteomics, and histologic

measurements, particularly at the 14 dpi interval post SARS-CoV-2 infection (**Figure 7A**).

MUC5AC was expressed basally at lower levels, its expression increased transiently with

infection, but the absolute RNA levels remained low compared to MUC5B (**Supplemental**

Figure 8A). Note that overall MUC5B RNA and protein levels, but not MUC5AC, correlated

well (**Supplemental Figure 8B**).

In parallel with increased mucin secretion, there was a significant upregulation at 7-14 dpi of a

broad class of ion transport genes that mediate fluid secretion (**Figure 7B**). A central pathway

mediating airway surface hydration includes the CFTR Cl$^-$ channel and regulators of CFTR Cl$^-$

channel fluid secretory activity (55). Both CFTR gene expression and multiple regulatory

components of CFTR activity were upregulated. In contrast, key genes involved in fluid

absorption, *e.g.*, *SCNN1β* and *SCNN1γ*, were not upregulated and clustered separately in the

heatmap. The mucin and ion transport gene expression signatures suggest that airway surfaces

post-infection upregulate pathways to maintain/restore mucociliary transport by secretion of a

well-hydrated mucus to offset loss of ciliation and "flush" viruses/shed cells from airway

surfaces.

Finally, airway epithelia can respond to infection with increased synthesis and secretion of host

defense proteins and small molecules. While annotated antioxidant genes were variable in their

response post-infection (**Supplemental Figure 8C**), secreted antioxidant proteins were routinely

increased post-infection (**Figure 7C and Supplemental Figure 8D**). In contrast, proteomics

revealed a striking reduction in secretion of other host defense proteins, *e.g.*, SCGB1A1 (**Figure**

7Di and Supplemental Figure 8E), and the pathway for antimicrobial peptides (which includes

lysozyme, lactoferrin, SLPI, S100A8/9, and BPIFA/B1) was amongst the most downregulated

proteomic pathway signatures across the entire study (**Figure 7Dii and Supplemental Figure**

8F) (56). Notably, no relationships were detected between the suppressor/non-suppressor state at

the RNA or protein level for secreted proteins, with reported antiviral effects, including

lactotransferrin, BPIFA1, BPIFB1, SLIPI, or MUC5B/MUC5AC mucins (data not shown). At

the RNA-only level, no relationships were observed between the suppressor vs. non-suppressor

state and beta, defensins, nitric oxide synthesis 1, 2, or 3, and cathelicidin (data not shown).

H. Comparison of Infection of HBE Cultures as a Function of the Sex of the Donor

Note, because the sexes were not perfectly matched across batches in the 14 day protocol

(**Supplemental Figure 1A**), a batch correction was necessary, which confounded the sex

analyses (see **Supplemental Methods**). However, because, as described below, female sex was

found to produce higher viral titers in the 14 day protocol which could have dominated over

technical batch variables, the Protocol 1, 14 day studies were supplemented by data from a

replicate single-batch 3 day study (Protocol 2) focused on the effects of sex on infectivity from

0-3 dpi (**Supplemental Figure 1B**). Each protocol is discussed separately below.

In the 14 day protocol (Protocol 1), female donor HBE cultures exhibited a more rapid rise in

SARS-CoV-2 infection and higher peak levels of SARS-CoV-2 infection than cultures from

male donors as indexed by viral titers and secreted NCAP protein (**Figure 8, Ai and ii,**

Supplemental Figure 9A). In contrast, the mean rates of suppression of viral titer, N TPM, and

extracellular viral proteins were not different between females and males (**Figure 8A, iii and iv,**

and Supplemental Figure 9A and B). Differences in cilia, ACE2, TMPRSS2 and TMEM106B

were not evident between the sexes that would explain the increase viral titer in females at 3 dpi

(**Supplemental Figure 9, C and D**). No differences were observed in SARS-CoV-2 mutation

load as a function of sex (**Supplemental Figure 8E**).

To test for sex-dependent differences in host epithelial genes that might relate to sex-dependent

differential SARS-CoV-2 infectivity, global transcriptomic differences between male and female

mock cultures were evaluated to characterize the state of gene expression prior to infection.

Notably, very few differentially expressed genes were observed between male vs. female

cultures over the 1-14 dpi interval in the mock infected cultures (**Figure 8B**). Nearly all the

differentially expressed genes in the absence of infection (mock) between female and male

cultures reflected the sex chromosome genes (**Figure 8C**), and no pathways were consistently

different in male vs. female mock cultures across the four timepoints measured (**Figure 8D**). The

major difference between the sexes after virus infection were noticed as an increase in the

number of genes upregulated in females at 3 dpi (**Figure 8C**). Further evaluation of those genes

identified them as ISGs, which correlated with the increase in viral titer in females at 3 dpi.

These ISGs were not differentially regulated between male and female 14 dpi when viral titers

were not different. We conclude that in this study, male and female differences in the airway

epithelial transcriptome were extremely rare, dominated by X-Y chromosome-specific genes,

with no one expression profile predicting differences in infectivity.

Given the importance of possible sex differences in SARS-CoV-2 infectivity observed in the first

protocol, the acquisition phase of infection in HBE cultures was repeated for same donors but

infected as a single batch (**Supplemental Figure 1B**, Protocol 2). In the replication study, while

similar trends for females to show early increases in infectivity, at 1 dpi, no differences were

observed at 2 and 3 dpi (**Figure 8Ei**). Importantly, the combined data from the two studies

revealed no significant difference in infectivity between the sexes (**Figure 8Eii**). Thus, we

conclude there was little significant difference in sex-related SARS-CoV-2 infection of human

airway epithelia.

I. SARS-CoV-2 Infection and repair of HBE cultures as a function of donor age:

The 14 day two-batch protocol (Protocol 1) was matched for age. There were no differences in

the rate of acquisition of SARS-CoV-2 infection over the 0-3 dpi interval as a function of age as

reflected in titer, N TPM, or extracellular N (**Figure 9, Ai and E, and Supplemental Figure**

10A). Further, there were no consistent differences in resolution over that 3-14 dpi interval as a

function of donor age despite a tendency for young cultures to be more likely to suppress viral

titers (**Figure 9A, ii and iii, and Supplemental Figure 10, A and E**). No differences in viral

mutation load were observed across ages (**Supplemental Figure 10F**), nor were differences in

kinetics or magnitude of IFN gene responses, LDHB, or HMGB1 release detected

(**Supplemental Figure 10, B and C**). These data are different than a smaller *in vitro* nasal

epithelial study (57) but are consistent with age-dependent data from bronchial epithelia *in vitro*

(29, 58) and *in vivo* nasal SARS-CoV-2 RNA measures in the respiratory system (14).

The PCA plot of the mock HBE RNAseq transcriptomic data showed no clear separation as a

function of age, and surprisingly few differences in gene expression across age using our

filtering criteria were found (**Figure 9D and Supplemental Figure 10 D**). We then sought age-

dependent differences using pathway analyses in mock infected cultures across all timepoints

(**Figure 9C;** see **Supplemental Table 2** for access to analyses**)**. While each individual mock

timepoints comparison produced pathways that survived statistical significance testing, the

patterns were complex. A selected set of these pathways was chosen to depict major patterns

(**Figure 9C, D**). A consistent upregulation was noted across time in the young vs. mature

comparison in pathways that contained genes involved in cell cycle and DNA repair. Very few

pathways were consistently downregulated in young vs. mature, a notable exception being

biological oxidations. Overall, we conclude that the data supports the concept that cultures from

donors of all ages are surprisingly similar at the gene expression level, consistent with the

absence of age-dependent differences in infectivity in Protocol 1 and, indeed, the replication

protocol (Protocol 2) (**Figure 9E**).

Evaluation of age-dependent transcriptional responses to SARS-CoV-2 infection with respect to

epithelial damage and repair also yielded complex pathway responses with age across time post-

infection (**Figure 9D**). Again, few consistent differences across age were noted across the entire

viral infection interval and ISG responses were similar across age groups (**Figure 9Fi**). The

tendency for cell cycle genes to be higher in young observed in mock cultures was maintained

after virus infection, except for 7 dpi where previous results show the highest cell cycling across

all ages (**Figure 6B**). In contrast, some of these genes were significantly downregulated in

elderly vs. mature after SARS-CoV-2 infection, indicating that the elderly may have reduced

capacity to cycle/repair after injury than young and mature cultures. The young donor cultures

also exhibited pathways indicating more robust DNA methylation (**Figure 9Fii**) with the elderly

showed reduced responses in these general pathways compared to the mature (or young) group.

In sum, we conclude that the respiratory epithelia of all ages exhibit similar baseline gene

expression properties and SARS-CoV-2 infectivity, but age-dependent differences in pathways

associated with repair were manifest.

J. Variables related to abnormal airway repair at 14 dpi *in vitro*:

The contributions of peak infection intensity (titer, TPM, NCAP) and epithelial damage (LDHB)

to a pathway-based index of failed epithelial repair (referred to as the repair index; see

Supplemental Methods) were tested. Surprisingly, no relationships between the intensity of

viral infection (**Figure 10A and Supplemental Figure 11, A and B**) and epithelial damage

(**LDHB; Figure 10B**) and the 14 dpi repair index were detected. Similarly, no relationships were

detected as a function of the sex of the donor (**Figure 10C**). In contrast, young age appeared to

be associated with an improved repair index (**Figure 10D**).

K. Repair processes reflect *in vivo* COVID:

We next asked whether genes that reflected failed return to a normal state, *i.e.*, failed repair, at 14

dpi in HBE cultures exhibited relevance to persistent long-COVID pulmonary disease. Analyses

of virus-infected vs. mock cultures identified 148 DEGs using an established threshold for

significance (see **Supplemental Methods**). We utilized this 14 dpi gene signature of "failed

repair" to query three datasets to address this question across two post-COVID lung disease

phenotypes.

We first analyzed spatial transcriptomics data from two cohorts with a post-COVID pulmonary

fibrosis phenotype. The first analysis focused on a reported autopsy study of 61 subjects ~ 30 d

post-SARS-CoV-2 symptom initiation with early pulmonary fibrotic histologic changes (46).

GSEA analyses revealed significant enrichment for the 14 dpi repair genes (e.g., *FCGBP*,

MUC5B, SERPINA3, IFI27, CLXL1) in persistently abnormal airway epithelia in this cohort

(**Figure 10E**). The second analysis focused on GeoMX spatial transcriptomics studies of

conducting airway epithelia of five subjects 6-12 mo post-initiation of SARS-CoV-2 symptoms

who exhibited persistent CT abnormalities and required video-assisted transthoracic surgery

(VATS) biopsies (**Supplemental Methods**). Histological evaluation of the biopsies revealed a

pulmonary fibrotic phenotype. Notably, the GSEA analysis again revealed significant enrichment

of the 14 dpi repair genes in diseased airway epithelial regions of the biopsied long-COVID

lungs (**Figure 10F**). Thus, the altered repair processes identified in 14 dpi HBE persist in the

airway regions of subjects with long-COVID pulmonary fibrotic phenotypes.

We next studied a long pulmonary COVID phenotype that manifests as chronic cough, sputum

production, and chest congestion. Recently, transbronchoscopic epithelial biopsies of subjects

exhibiting this phenotype persistently for ~ 18 mo post-SARS-CoV-2 infection vs. subjects who

resolved symptoms post-SARS-CoV-2 were reported (59). The 14 dpi HBE SARS-CoV-2 DEG

signature was enriched in the symptomatic as compared to non-symptomatic/control post-SARS-

CoV-2 infection groups, suggesting persistently abnormal repair contributes to the long-COVID

bronchitic phenotype **(Figure 10G)**. A pathway analysis was performed on the gene set

representing failed repair. As predicted, the genes representing the ISG pathway were enriched

and correlated with the presence of viral transcripts (**Figure 10H**). Other upregulated pathways

in this gene set included neutrophil, complement, hypoxia, and interleukin signaling (**Figure**

10I).

Discussion:

The clinical outcomes of SARS-CoV-2 infections vary widely, reflecting a complex interplay

between the virus and host defense and reparative properties. This study explored potential age-

and sex-dependent contributions of respiratory epithelia to SARS-CoV-2 outcomes through 14

days post-infection. This study also offered the opportunity to investigate relationships between

in vitro intermediate-term repair (14 d) with long-term epithelial properties in subjects with long

COVID respiratory syndromes.

No differences in the rates of acquisition or peak viral titers, TPM, viral proteins, or viral

mutation load were consistently observed across cultures derived from children, mature adults, or

the elderly, consistent with previous reports of bronchial epithelia (29, 58). Key cell biologic

variables reported to govern infection rates also did not differ across age groups, including ACE2

expression, TMPRSS2 expression, culture ciliation, or kinetics/magnitude of IF responses, again

consistent with previous reports (29, 30, 60). RNA bulk-seq analyses of paired mock HBE

cultures prior to infection showed little differential gene expression in single genes across all

donor ages in PCA plots and DEG analyses. However, pathway analyses revealed an

upregulation in the young referenced to maturity of cell cycling and DNA repair pathways.

While all age groups exhibited similar epithelial morphology at d14, dominated by mucus

metaplasia, the younger subject cultures exhibited more robust cell cycling, DNA repair, and

oxidative stress pathway responses over the 3-14 dpi interval. Similar patterns of more

rapid/efficient repair have been observed in young vs. elderly subject cultures after a variety of

biologic and chemical insults (61), suggesting the young have in general more robust reparative

capacities in response to injury. The relatively consistent gene expression patterns observed after

virus across ages in these epithelial cultures suggest that immune cell function, not intrinsic

epithelial function, likely account for the age dependence of viral titer and severity outcomes

from SARS-CoV-2 infections (62-64). The childhood respiratory immune system has been

reported to be more versatile/trained to respond to a SARS-CoV-2 infection and prevent spread

to the lung with worsened clinical outcomes (13, 65-67). Conversely, a senescent immune

system has been posited to account for the worsened outcomes in the elderly (62, 63).

Regarding sex, our aggregate studies revealed no differences in SARS-CoV-2 infection in female

vs. male human bronchial epithelial cells, similar to a report of human nasal cultures in which no

differences in SARS-CoV-2 titer were detected as a function of sex (68). Epidemiologic studies

have clearly established that males, especially older males, exhibit more severe COVID-19

disease, but there is a paucity of large epidemiologic studies that have reported the differences in

titer in males vs. females *in vivo* (9). The two available studies described mixed findings, with a

small study of US Marine recruits reporting lower SARS-CoV-2 Ct values for males (9),

whereas a larger Saudi Arabian study reported a significantly lower Ct value in females of all

ages than males (62, 63).

The absence of a large effect of sex on SARS-CoV-2 epithelial infectivity is consistent with

analyses of female vs. male in mock (non-infected) cultures. PCA or DEG analyses of bulk-

RNAseq data revealed surprisingly few differences, limited to X and Y chromosomes, in

baseline gene expression, including ACE2 and TMPRSS2, between male and females (69). Note,

the Human Cell Atlas has released data describing multiple pulmonary epithelial cells as a

function of sex (70). Like our study, no differences in gene expression were observed, suggesting

human respiratory epithelia are not sex hormone responsive.

Combining the age and sex data into a larger dataset permitted insights into the airway epithelial

cell biologic response to the acute infection and repair processes. Aspects of the acute 3 dpi

response have been widely reported, including the selective infection of ciliated cells with

apoptotic and likely necrotic cell death (4, 28, 71, 72). The cell signaling processes during this

period are complex, with DAMP release, *e.g.*, HMGB1 and ATP, but also recruitment of anti-

inflammatory extra-cellular signals, *e.g.*, MTA. Major cell biologic responses at this peak period

also included suppression of mitochondrial and ribosomal gene expression. Coincident with

these responses were striking increases in expression of genes associated with histone acetylation

and inflammation. These responses reflect complex signaling cascades involving infected cells

and communication *in vivo* with immune/inflammatory cells via IF, DAMP, and inflammatory

mediators/cytokines.

Post-viral bacterial infections in the quasi-acute setting (wks) are common with respiratory

viruses in general, and severe COVID-19 subjects have an ~ 30% incidence of bacterial

superinfections (73). Many of these bacterial infections involve infection of airway mucus plugs

(46). Singanayagam et al., utilizing a rhinovirus challenge model in COPD subjects,

demonstrated that post-viral bacterial infections reflected neutrophil destruction of host airway

secretion antimicrobial substances and abnormal mucus production (74). Mucociliary clearance

is a key defense mechanism combating airway infection and exhibits a complex interplay

between ciliated cell numbers and mucus properties. Mucin secretion was upregulated, likely in

part due to EGFR and IL1R1 signaling, in SARS-CoV-2-infected HBE cultures (46). However,

mucins must be well hydrated to be transported effectively by MCC or the backup cough

mechanism. The upregulation of the dominant ion channel mediating fluid secretion, *i.e.*, CFTR,

coupled to an absence of upregulation of the channel that mediates opposing fluid absorption,

i.e., ENaC, generates a scenario whereby newly secreted mucus is sufficiently hydrated to

mediate effective mucus clearance. However, the reduction post-SARS-CoV-2 infection in

ciliated cell numbers, with a concomitant loss of cilial force and mucus hydration

mechanosensing, can produce counterposing effects on MCC and cough clearance, particularly

in small airways, that produce mucus plugging in COVID lungs (46).

Infection of mucus plugs may be promoted by the absence of activities of antimicrobial

substances required for bacterial suppression on airway surfaces. In addition to neutrophil

cleavage of these substances post-viral infection, SARS-CoV-2 infection downregulated in

airway epithelia a complex of antimicrobial peptides, including CCSP, lactoferrin, and lysozyme

over the 3-14 dpi interval (74, 75). These molecules are key for suppressing bacterial growth

over intervals required for bacterial clearance by the MCC system, and the limitation of secreted

antimicrobial substances in the context of hampered MCC provides favorable conditions for

secondary airway bacterial infections (76).

Our study design allowed for detailed analyses of epithelial repair over 14 dpi in response to

SARS-CoV-2 infection. Airway epithelia emerged from peak infection into a phase at 7 dpi of

persistent but waning SARS-CoV-2 infection and repair/disrepair. By 14 dpi, airway epithelia

repaired via remodeling pathways that produced an abnormally mucus metaplastic, less ciliated

epithelium. This result likely is mediated in part by an increase in basal cell activation/cycling

and a skewing toward a mucus metaplastic phenotype due in part to increases in EGF ligand

production, *e.g.*, amphiregulin, and EFF-R signaling (48, 49). Our data describing the arrest of

ciliated cell maturation at the deuterosomal stage are consistent with this notion (40, 77). The

major variable identified in our study that associated with repair at 14 dpi was age, with young

repairing better, whereas no differences based on infection intensity or sex were detected.

Presumably, in most people post-SARS-CoV-2 infection, the epithelium continues to be repaired

over weeks *in vivo* with resolution of symptoms. However, a fraction of people post-SARS-CoV-

2 infection manifest "long pulmonary COVID" syndromes. Although multiple phenotypes are

reported associated with long pulmonary COVID, chronic bronchitic and pulmonary fibrotic

phenotypes are amongst the most common (59, 78-80). One mechanism that may contribute to

long-COVID pulmonary disease is the failure of infected pulmonary epithelia to repair. This

mechanism almost certainly contributes to the failure of infected alveolar AT2 cells to replenish

both AT2 and AT1 cells in long-COVID subjects with a resultant chronic fibrotic phenotype (81-

84).

Our data demonstrating the persistence of the HBE 14 dpi DEG signature in chronically diseased

airway epithelia in people with long-COVID fibrotic and bronchitic phenotypes suggest

persistent abnormal airway epithelial repair contributes to the pathogenesis of the airway

component of long-COVID pulmonary disease. Analyses of the pathways characterizing this

repair DEG set identified persistent ISG responses that correlated with the persistence of viral

transcripts in HBE cells at 14 dpi. It has been previously shown that chronically elevated ISG

expression in response to poly-IC exposure is associated with airway epithelial metaplasia,

similar to reports in alveolar epithelia (85, 86). One speculation that may describe persistent ISG

expression and airway metaplasia in some long-COVID individuals is a persistent low level of

non-infectious SARS-CoV-2 RNA expression in airway epithelial cells not cleared via

immunologic clearance mechanisms.

Our study has limitations. First, our study employed cultures of well-differentiated airway

epithelia. Whereas this design queries the intrinsic activity of the epithelium, it does not reprise

the activity of an epithelium *in vivo* exposed to the full spectrum of immune and stromal cells,

nor can it reflect the normal clearance of virus via immune cell activity. Thus, the culture

approach may have accounted for failure to identify key genes related to age-dependent host

antiviral defense *in vivo*. Second, our cultures were not exposed to media containing sex

hormones that may have been appropriate for sex. Third, the experimental sampling intervals

were not daily, making interpretation of rates of accumulation of virus/secreted proteins difficult.

Normalization was used to mitigate this problem. Fourth, while relatively large for a study in cell

culture, the study is expected to be underpowered to capture the entirety of the variability in the

human population.

In summary, our studies demonstrate that SARS-CoV-2 infection of airway epithelia leaves the

airway epithelium at 14 dpi in a repairing but complex state characterized by impaired mucus

transport, host defense protein secretion, and hyperinflammation. Young age, but neither sex nor

the peak intensity of the SARS-CoV-2 infection, modulates the post-viral repair state, consistent

with improved outcomes of the young (17, 26, 67, 87). The incomplete/abnormal repair state is

predicted to render the airway epithelium over a quasi-acute (days) post-infection interval

vulnerable to bacterial superinfections. The persistence of a failed repair state over the longer

term (months) may contribute to post-COVID pulmonary syndromes, including an airways

component of fibrotic sequelae and a bronchitic phenotype of cough and sputum production. A

persistent airway epithelial ISG response, possibly in response to poorly cleared viral RNA, may

be a driver of aspects of these long-COVID syndromes.

Methods Section

A. Experimental Design for *In Vitro* Studies

The experimental design is outlined in **Supplemental Figure 1**, with the technical details of each

individual assay provided in the **Supplement Material**. In broad terms, air–liquid interface

(ALI), well-differentiated HBE cultures were infected with SARS-CoV-2 and collected for

analyses as indicated (88). Cells were obtained under the protocol #03-1396 approved by the

University of North Carolina at Chapel Hill Biomedical Institutional Review Board in the

Marsico Lung Institute Tissue Procurement and Cell Culture Core. Three age groups were

studied: Young (age 0-8); Mature (age 21-29): Elderly (> 69). A replication protocol studied the

same donors in a single batch over a 3 dpi interval (**Supplemental Figure 1B**). Sample specifics

are provided in **Supplemental Table 1.** Key assays conducted consisted of titer, bulk RNAseq,

and proteomics from apical secretions. Key analyses included determination of differential gene

and protein expression (including pathway analyses), development of heatmaps, and an index to

describe disease repair. The index was tested against candidate variables hypothesized to govern

repair status, including infection intensity, sex, and donor age. Differences of means of outcome

measurements between experimental groups were tested with linear models, or in the case of

repeated measures design, with linear mixed-effect models. Analyses methods are provided in

detail in **Supplemental Material,** with details provided in figure legends as appropriate. Full

analyses of the results are provided in **Supplemental Files 1-24** with a description of those files

provided in **Supplemental Table 2**.

Acknowledgments: The authors wish to thank Eric Roe at the Marsico Lung Institute for expert

editorial and administrative assistance in the preparation of the manuscript. We also

acknowledge the University of North Carolina Pathology Services Core for providing

histological samples, especially the director of this core, Dr. Gabriela De la Cruz and her staff.

Funding Statement: The work is supported by National Institutes of Health grants P30

DK065988, R01 AI089728, and U19 AI116484; by Rapidly Emerging Antiviral Drug

Development Initiative (READDI) at the University of North Carolina at Chapel Hill,

appropriated by the North Carolina General Assembly; and by the Cystic Fibrosis Foundation

grants BOUCHE19R0, ESTHER24R0, and 00167G220 (Pickles).

References

1.   Ellinghaus D, et al. Genomewide Association Study of Severe Covid-19 with Respiratory

Failure. *N Engl J Med.* 2020;383(16):1522-1534.

2.   Kasela S, et al. Genetic and non-genetic factors affecting the expression of COVID-19-

relevant genes in the large airway epithelium. *Genome Med.* 2021;13(1):66.

3.   Shelton JF, et al. The UGT2A1/UGT2A2 locus is associated with COVID-19-related loss

of smell or taste. *Nat Genet.* 2022;54(2):121-124.

4.   Bridges JP, et al. Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19.

Thorax. 2022;77(2):203-209.

5.   Yang X, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2

pneumonia in Wuhan, China: a single-centered, retrospective, observational study.

Lancet Respir Med. 2020;8(5):475-481.

6.   Hastie E, et al. Association between SARS-CoV-2 Viral Load and Patient Symptoms and

Clinical Outcomes Using Droplet Digital PCR. *Viruses.* 2023;15(2).

7.   Jovanoski N, et al. Severity of COVID-19 and adverse long-term outcomes: a

retrospective cohort study based on a US electronic health record database. *BMJ Open.*

2021;11(12):e056284.

8.   Pujadas E, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. *Lancet Respir*

Med. 2020;8(9):e70.

9.   Sauerwald N, et al. Pre-infection antiviral innate immunity contributes to sex differences

in SARS-CoV-2 infection. *Cell Syst.* 2022;13(11):924-931.e924.

10.   Regis E, et al. Sex differences in innate anti-viral immune responses to respiratory

viruses and in their clinical outcomes in a birth cohort study. *Sci Rep.* 2021;11(1):23741.

11.   Scully EP, et al. Considering how biological sex impacts immune responses and COVID-

19 outcomes. *Nat Rev Immunol.* 2020;20(7):442-447.

12.   Ursin RL, Klein SL. Sex Differences in Respiratory Viral Pathogenesis and Treatments.

Annu Rev Virol. 2021;8(1):393-414.

13.   O'Driscoll M, et al. Age-specific mortality and immunity patterns of SARS-CoV-2.

Nature. 2021;590(7844):140-145.

14.   Koch CM, et al. Age-related Differences in the Nasal Mucosal Immune Response to

SARS-CoV-2. *Am J Respir Cell Mol Biol.* 2022;66(2):206-222.

15.   Pierce CA, et al. COVID-19 and children. *Science.* 2022;377(6611):1144-1149.

16.   Nakakubo S, et al. Associations of COVID-19 symptoms with omicron subvariants BA.2

and BA.5, host status, and clinical outcomes in Japan: a registry-based observational

study. *Lancet Infect Dis.* 2023;23(11):1244-1256.

17.   Winkley K, et al. Immune cell residency in the nasal mucosa may partially explain

respiratory disease severity across the age range. *Sci Rep.* 2021;11(1):15927.

18.   Nakanishi T, et al. Age-dependent impact of the major common genetic risk factor for
727   COVID-19 on severity and mortality. *J Clin Invest.* 2021;131(23).

728   19.   Williamson EJ, et al. Factors associated with COVID-19-related death using
729   OpenSAFELY. *Nature.* 2020;584(7821):430-436.

730   20.   Schneider JL, et al. The aging lung: Physiology, disease, and immunity. *Cell.*
731   2021;184(8):1990-2019.

732   21.   Hao S, et al. Long-Term Modeling of SARS-CoV-2 Infection of In Vitro Cultured
733   Polarized Human Airway Epithelium. *mBio.* 2020;11(6).

734   22.   Hou YJ, et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in
735   the Respiratory Tract. *Cell.* 2020;182(2):429-446.e414.

736   23.   Killingley B, et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human
737   challenge in young adults. *Nat Med.* 2022;28(5):1031-1041.

738   24.   Kim D, et al. The Architecture of SARS-CoV-2 Transcriptome. *Cell.* 2020;181(4):914-
739   921.e910.

740   25.   Walsh KA, et al. The duration of infectiousness of individuals infected with SARS-CoV-
741   2. *J Infect.* 2020;81(6):847-856.

742   26.   Loske J, et al. Pre-activated antiviral innate immunity in the upper airways controls early
743   SARS-CoV-2 infection in children. *Nat Biotechnol.* 2022;40(3):319-324.

744   27.   Hoffmann M, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
745   Blocked by a Clinically Proven Protease Inhibitor. *Cell.* 2020;181(2):271-280.e278.

746   28.   Morrison CB, et al. SARS-CoV-2 infection of airway cells causes intense viral and cell
747   shedding, two spreading mechanisms affected by IL-13. *Proc Natl Acad Sci U S A.*
748   2022;119(16):e2119680119.

749   29.   Hysenaj L, et al. SARS-CoV-2 infection of airway organoids reveals conserved use of

750   Tetraspanin-8 by Ancestral, Delta, and Omicron variants. *Stem Cell Reports.*

751   2023;18(3):636-653.

752   30.   Inde Z, et al. Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death

753   programs correlates with COVID-19 severity. *Sci Adv.* 2021;7(34).

754   31.   Buqaileh R, et al. Can cilia provide an entry gateway for SARS-CoV-2 to human ciliated

755   cells? *Physiol Genomics.* 2021;53(6):249-258.

756   32.   Cheemarla NR, et al. Dynamic innate immune response determines susceptibility to

757   SARS-CoV-2 infection and early replication kinetics. *J Exp Med.* 2021;218(8).

758   33.   Sungnak W, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial

759   cells together with innate immune genes. *Nat Med.* 2020;26(5):681-687.

760   34.   Ziegler CGK, et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in

761   Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.

762   *Cell.* 2020;181(5):1016-1035.e1019.

763   35.   Menachery VD, et al. Pathogenic influenza viruses and coronaviruses utilize similar and

764   contrasting approaches to control interferon-stimulated gene responses. *mBio.*

765   2014;5(3):e01174-01114.

766   36.   Jackson CB, et al. Mechanisms of SARS-CoV-2 entry into cells. *Nat Rev Mol Cell Biol.*

767   2022;23(1):3-20.

768   37.   Xu D, et al. PLSCR1 is a cell-autonomous defence factor against SARS-CoV-2 infection.

769   *Nature.* 2023;619(7971):819-827.

770   38.   Blanco-Melo D, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development

771   of COVID-19. *Cell.* 2020;181(5):1036-1045.e1039.

772   39.   Broadbent L, et al. An endogenously activated antiviral state restricts SARS-CoV-2

773   infection in differentiated primary airway epithelial cells. *PLoS One.*

774   2022;17(4):e0266412.

775   40.   Gamage AM, et al. Human Nasal Epithelial Cells Sustain Persistent SARS-CoV-2

776   Infection In Vitro, despite Eliciting a Prolonged Antiviral Response. *mBio.*

777   2022;13(1):e0343621.

778   41.   Hatton CF, et al. Delayed induction of type I and III interferons mediates nasal epithelial

779   cell permissiveness to SARS-CoV-2. *Nat Commun.* 2021;12(1):7092.

780   42.   COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-

781   19. *Nature.* 2021;600(7889):472-477.

782   43.   Li S, et al. SARS-CoV-2 Z-RNA activates the ZBP1-RIPK3 pathway to promote virus-

783   induced inflammatory responses. *Cell Res.* 2023;33(3):201-214.

784   44.   Simpson J, et al. Respiratory Syncytial Virus Infection Promotes Necroptosis and

785   HMGB1 Release by Airway Epithelial Cells. *Am J Respir Crit Care Med.*

786   2020;201(11):1358-1371.

787   45.   Chandler JD, Esther CR, Jr. Metabolomics of airways disease in cystic fibrosis. *Curr*

788   *Opin Pharmacol.* 2022;65:102238.

789   46.   Kato T, et al. Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung

790   Disease. *Am J Respir Crit Care Med.* 2022;206(11):1336-1352.

791   47.   Lewis M, Stracker TH. Transcriptional regulation of multiciliated cell differentiation.

792   *Semin Cell Dev Biol.* 2021;110:51-60.

48.   Venkataraman T, et al. Overactive Epidermal Growth Factor Receptor Signaling Leads to

Increased Fibrosis after Severe Acute Respiratory Syndrome Coronavirus Infection. *J*

Virol. 2017;91(12).

49.   Venkataraman T, Frieman MB. The role of epidermal growth factor receptor (EGFR)

signaling in SARS coronavirus-induced pulmonary fibrosis. *Antiviral Res.* 2017;143:142-

150.

50.   Coppé JP, et al. The senescence-associated secretory phenotype: the dark side of tumor

suppression. *Annu Rev Pathol.* 2010;5:99-118.

51.   Han J, et al. Hypoxia induces adrenomedullin from lung epithelia, stimulating ILC2

inflammation and immunity. *J Exp Med.* 2022;219(6).

52.   Hill DB, et al. Physiology and Pathophysiology of Human Airway Mucus. *Physiol Rev.*

2022;102(4):1757-1836.

53.   Li Q, et al. Mucociliary transport deficiency and disease progression in Syrian hamsters

with SARS-CoV-2 infection. *JCI Insight.* 2023;8(1).

54.   Boucher RC. Muco-Obstructive Lung Diseases. *N Engl J Med.* 2019;380(20):1941-1953.

55.   Ghigo A, et al. Cell signaling and regulation of CFTR expression in cystic fibrosis cells

in the era of high efficiency modulator therapy. *J Cyst Fibros.* 2023;22 Suppl 1:S12-s16.

56.   Akram KM, et al. An innate defense peptide BPIFA1/SPLUNC1 restricts influenza A

virus infection. *Mucosal Immunol.* 2018;11(1):71-81.

57.   Woodall MNJ, et al. Age-specific nasal epithelial responses to SARS-CoV-2 infection.

Nat Microbiol. 2024;9(5):1293-1311.

58.   Zhao C, et al. Activation of STAT3-mediated ciliated cell survival protects against severe

infection by respiratory syncytial virus. *J Clin Invest.* 2024;134(21).

59.   Gerayeli FV, et al. Single-cell sequencing reveals cellular landscape alterations in the

airway mucosa of patients with pulmonary long COVID. *Eur Respir J.* 2024;64(5).

60.   Tao Y, et al. Preliminary analyses of scRNA sequencing and immunohistochemistry of

children's lung tissues indicate the expression of SARS-CoV-2 entry-related genes may

not be the key reason for the milder syndromes of COVID-19 in children. *Clin Transl*

Med. 2021;11(5):e300.

61.   Balázs A, et al. Age-Related Differences in Structure and Function of Nasal Epithelial

Cultures From Healthy Children and Elderly People. *Front Immunol.* 2022;13:822437.

62.   Mahallawi WH, et al. Association of Viral Load in SARS-CoV-2 Patients With Age and

Gender. *Front Med (Lausanne).* 2021;8:608215.

63.   Euser S, et al. SARS-CoV-2 viral-load distribution reveals that viral loads increase with

age: a retrospective cross-sectional cohort study. *Int J Epidemiol.* 2022;50(6):1795-1803.

64.   Chua RL, et al. COVID-19 severity correlates with airway epithelium-immune cell

interactions identified by single-cell analysis. *Nat Biotechnol.* 2020;38(8):970-979.

65.   Beer J, et al. Impaired immune response drives age-dependent severity of COVID-19. *J*

Exp Med. 2022;219(12).

66.   Bartsch YC, et al. Humoral signatures of protective and pathological SARS-CoV-2

infection in children. *Nat Med.* 2021;27(3):454-462.

67.   Yoshida M, et al. Local and systemic responses to SARS-CoV-2 infection in children and

adults. *Nature.* 2022;602(7896):321-327.

68.   Brocke SA, et al. Woodsmoke particle exposure prior to SARS-CoV-2 infection alters

antiviral response gene expression in human nasal epithelial cells in a sex-dependent

manner. *Am J Physiol Lung Cell Mol Physiol.* 2022;322(3):L479-l494.

69.   Silveyra P, et al. Sex and Gender Differences in Lung Disease. *Adv Exp Med Biol.*

840   2021;1304:227-258.

841   70.   Sikkema L, et al. An integrated cell atlas of the lung in health and disease. *Nat Med.*

842   2023;29(6):1563-1577.

843   71.   Robinot R, et al. SARS-CoV-2 infection induces the dedifferentiation of multiciliated

844   cells and impairs mucociliary clearance. *Nat Commun.* 2021;12(1):4354.

845   72.   Zhu N, et al. Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human

846   airway epithelial cells. *Nat Commun.* 2020;11(1):3910.

847   73.   Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in

848   Wuhan, China. *Lancet.* 2020;395(10223):497-506.

849   74.   Singanayagam A, et al. Airway mucins promote immunopathology in virus-exacerbated

850   chronic obstructive pulmonary disease. *J Clin Invest.* 2022;132(8):e120901.

851   75.   McElvaney OF, et al. Protease-anti-protease compartmentalization in SARS-CoV-2

852   ARDS: Therapeutic implications. *EBioMedicine.* 2022;77:103894.

853   76.   Ganz T. Antimicrobial polypeptides in host defense of the respiratory tract. *J Clin Invest.*

854   2002;109(6):693-697.

855   77.   Wu K, et al. Lung Remodeling Regions in Long-Term Coronavirus Disease 2019 Feature

856   Basal Epithelial Cell Reprogramming. *Am J Pathol.* 2023.

857   78.   Duong-Quy S, et al. Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures:

858   A Narrative Review. *Pulm Ther.* 2023;9(3):295-307.

859   79.   McGroder CF, et al. Pulmonary fibrosis 4 months after COVID-19 is associated with

860   severity of illness and blood leucocyte telomere length. *Thorax.* 2021;76(12):1242-1245.

80.   Spagnolo P, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? *Lancet*

Respir Med. 2020;8(8):750-752.

81.   Barkauskas CE, et al. Type 2 alveolar cells are stem cells in adult lung. *J Clin Invest.*

2013;123(7):3025-3036.

82.   Strunz M, et al. Alveolar regeneration through a Krt8+ transitional stem cell state that

persists in human lung fibrosis. *Nat Commun.* 2020;11(1):3559.

83.   Alysandratos KD, et al. Epithelial Stem and Progenitor Cells in Lung Repair and

Regeneration. *Annu Rev Physiol.* 2021;83:529-550.

84.   Xie T, et al. Abnormal respiratory progenitors in fibrotic lung injury. *Stem Cell Res Ther.*

2022;13(1):64.

85.   Onufer AP, et al. Influenza virus-induced type I interferons disrupt alveolar epithelial

repair and tight junction integrity in the developing lung. *Mucosal Immunol.* 2025.

86.   Major J, et al. Type I and III interferons disrupt lung epithelial repair during recovery

from viral infection. *Science.* 2020;369(6504):712-717.

87.   Freire PP, et al. The relationship between cytokine and neutrophil gene network

distinguishes SARS-CoV-2-infected patients by sex and age. *JCI Insight.* 2021;6(10).

88.   Hou YJ, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and

transmission in vivo. *Science.* 2020;370(6523):1464-1468.

Figure 1. Indices of SARS-CoV-2 infection of all human bronchial epithelial (HBE) donor cultures with day post-infection (dpi). (A) SARS-CoV-2 titers over the 14 dpi interval, with each donor shown as connecting lines. HBE donor cultures that "suppressed" viral titers at d14 shown in blue. "Non-suppressors" are shown in orange. **(B)** Intracellular SARS-CoV-2 nucleoprotein (N) transcripts per million (TPM) by dpi for each donor culture. **(C)** Luminal extracellular viral NCAP protein by dpi for each donor. **(D)** Correlations between indices of SARS-CoV-2 infection. Shaded areas represent the 95% confidence interval. **(Di)** Correlation between viral titer and viral N TPM for each dpi. $p < 0.0001$. **(Dii)** Correlation between titer and nucleocapsid protein (NCAP) levels. $p < 0.0001$. Note that several 14 dpi samples are NCAP-positive and titer-negative. **(Diii)** Correlation between NCAP protein and SARS-CoV-2 viral N TPM for each dpi. $p < 0.0001$. Pearson correlation tests were used to calculate p-value and R^2. **(E)** Relationships between indices of SARS-CoV-2 infection with dpi. **(Ei)** Ratio of total intracellular viral TPM vs. titer by dpi. **(Eii)** Ratio of NCAP protein vs. titer by dpi.

Figure 2. Host factor vs. peak viral titer relationships. Relationships between peak SARS-CoV-2 infection at 3 dpi and **(A)** long-form *ACE2* expression (p=0.24), **(B)** *TMPRSS2* expression (p=0.00249), **(C)** *TMEM106B* expression (p = 0.0049), **(D)** median cilia gene expression (p = 0.173), **(E)** HBE viral entry gene RNA score (p = 0.00071), and **(F)** *PLSCR1* expression (p = 0.0078). TPM=transcripts per million. All parameters listed on the X axes in A-F are measured from mock infected cultures at 1 dpi. Pearson correlation tests were used to calculate p-value and R^2. Shaded areas represent the 95% confidence intervals.

904

905 **Figure 3. Interferon (IF) and interferon-stimulated gene (ISG) response kinetics to SARS-CoV-2**

906 **infection. (A)** Box plots describing the expression values (in log10 scale plus offset of 1;

907 TPM=transcripts per million) for HBE interferon responses over 14 dpi in mock and infected cultures for

908 **(Ai)** *IFNL1,* **(Aii)** *IFNL2,* **(Aiii)** *IFNL3,* and **(Aiv)** *IFNB1***. (B)** HBE ISGs post-SARS-CoV-2 infection.

909 **(Bi)** Heatmap describing pattern of ISG gene expression from 1-14 dpi. **(Bii)** Box plot describing level of

910 mean ISG expression (TPM) for virus vs. mock from 1-14 dpi. **(C)** ISG proteins in luminal secretions

911 from SARS-CoV-2-infected HBE cultures spanning 1-14 dpi. **(Ci)** Heatmap describing individual ISG

912 proteins identified on HBE culture surfaces (normalized and imputed levels as described in methods).

913 **(Cii)** Box plot describing mean level of secreted ISG protein for virus vs. mock from 1-14 dpi. **(D)**

914 Relationships between viral infection, interferon (IFN), and ISG responses by dpi. Note, each parameter

915 normalized to 100% mean peak response and depicted separately for HBE culture titer suppressors (blue)

916 vs. non-suppressors (yellow). **(Di)** Mean percent of peak titers vs. dpi. **(Dii)** Mean percent nucleocapsid

(N) transcript levels vs. dpi. **(Diii)** Mean percent IFN responses vs. dpi. **(Div)** Mean percent ISG
responses vs. dpi. Genes associated with the heatmap are listed in **Supplemental File 1.** Statistics utilized
linear mixed models using tiered statistical testing: a) Univariate gene expression (TPM) by treatment
(using symbol *; top row), b) Linear models with biological variables (age group + sex + median ciliated
genes) and treatment (using symbol †; middle row), c) Linear models with biological and QC variables
(age group + sex + median ciliated genes + batch + PC1) and treatment (most conservative, using symbol
‡; bottom row). The number of symbols represents statistical significance: ns = not significant; one
symbol = $p < 0.05$; two symbols = $p < 0.01$, three symbols = $p < 0.001$; four symbols = $p < 0.0001$.
925

Figure 4. Global HBE responses to SARS-CoV-2 infection. **(A)** PCA plot representing the global bulk RNA transcriptome in mock and virus-infected cultures. All dpi are represented. **(B)** PCA plots representing global RNA transcriptome in mock and virus-infected cultures at the dpi indicated. In A and B, ellipses are drawn at 95% level assuming normal distributions of samples per group. PC=principal component. **(C)** Differentially expressed genes (DEGs) at the dpi indicated, showing number of regulated genes in both directions comparing virus-infected to mock treated cultures [(upregulated by SARS-CoV-2 in the upward bar (open); and downregulated in the downward bar (closed)]. DEGs represented are filtered at adjusted P-value of <0.05 and absolute log2 fold-change >1 with an average expression >0 (log2; or roughly TMP>1). **(D)** Venn diagrams depicting the overlap of DEGs between mock and SARS-CoV-2 infection across dpi groups. **(Di)** All DEGs; **(Dii)** DEGs upregulated by virus; **(Diii)** DEGs downregulated genes by virus. Filtering as in (C). **(E)** Heatmap of selected significant gene expression pathways identified as differentially expressed from the Reactome + custom pathway annotation set between virus infected vs. mock at indicated dpi. NES=normalized enrichment score. Red represents pathways upregulated by virus, blue represents pathways downregulated by virus.

Figure 5. Human bronchial epithelial culture responses at peak SARS-CoV-2 infection. (A)
Measures of cell death. **(Ai)** TUNEL assay quantification at 3 and 14 dpi in mock and infected cultures.
** = p < 0.01. **(Aii)** Box plots depicting LDHB release onto SARS-CoV-2-infected HBE culture surfaces
spanning 1-14 dpi. **(Aiii)** Box plots depicting high mobility group box 1 (HMGB1) HBE apical surface
protein levels spanning 1-14 dpi. **(B)** Measures of metabolites. Box plots depicting **(Bi)** total adenosine
triphosphate (ATP) metabolites and **(Bii)** uric acid (UAC) concentrations, **(Biii)** MTA = methyl-thio-
adenosine; **(Biv)** Ade = adenosine; and **(Bv)** Met = methionine as measured by mass spectroscopy in
secretions at the indicated dpi. * = p < 0.05; **p<0.01. **(C-E)** Examples of pathway responses to peak

SARS-CpV-2 infection. **(Ci)** Heatmap of nuclear-encoded mitochondrial genes post-SARS-CoV-2 HBE
culture infection. **(Cii)** Box plots showing average gene expression per donor culture for mock and
SARS-CoV-2-infected cultures over dpi. **(Di)** Heatmap describing histone acetylation gene expression
over time post-SARS-CoV-2 infection. **(Dii)** Box plot describing average histone acetylation gene
expression levels per HBE culture donor for mock and SARS-CoV-2-infected cultures with time. **(Ei)**
Heatmap describing individual genes in the KEGG pathway for cytokines and receptors regulated by
SARS-CoV-2 infection over dpi. **(Eii)** Box plots showing average gene expression per HBE donor culture
for mock and SARS-CoV-2-infected cultures over dpi. Labels in Ci apply to all heatmaps. Statistics
conducted and symbols as described in **Figure 3** legend.

Figure 6. SARS-CoV-2-induced remodeling, senescence/inflammation, and repair in human bronchial epithelial cell cultures. (A) Ciliated cell quantification with infection. **(Ai)** Morphometric measurement of ciliation [cilia-covered apical surface/basement membrane (BM); measurement designated nCilia BM on axis label] for mock and SARS-CoV-2-infected HBE cultures at 3 and 14 dpi. **(Aii)** nCilia BM vs. median multi-ciliated cell gene expression pathway at 14 dpi. Mock HBE slope = 0.286 (SE 0.047), SARS-CoV-2-infected slope = 0.086 (SE 0.011) (delta = 0.176, SE = 0.043, p < 0.00027). Shaded areas represent the 95% confidence intervals. **(Aiii)** Mean deuterosomal cell gene expression for mock and SARS-CoV-2-infected cultures over dpi. **(B)** Cell cycling. **(Bi)** Heatmap depicting cell cycle gene expression over time post-infection. **(Bii)** Box plot depicting mean cell cycle gene expression (transcripts per million = TPM) over time post-infection. **(C)** EGFR signaling. **(Ci)** Heatmap depicting EGFR signaling genes as a function of time post-infection. **(Cii)** Box plots depicting mean EGFR signaling pathway gene expression over time post-infection. **(D)** Mitochondrial encoded

973   genes. **(Di)** Heatmap depicting mitochondrial encoded genes over time post-infection. **(Dii)** Box plot
974   depicting mean mitochondrial gene expression over time post-infection. Statistics conducted and symbols
975   as described in **Figure 3** legend. Headers in Bi apply to all heatmaps.
976

Figure 7. Human bronchial epithelial host mucosal defense responses to SARS-CoV-2 infection. (A)
Secretory mucin expression. **(Ai)** Box plots depicting *MUC5B* RNA expression in mock vs. SARS-CoV-2-infected HBE cultures over dpi. **(Aii)** MUC5B protein secreted onto apical surfaces of mock vs. SARS-CoV-2-infected HBE cultures with time. **(Aiii)** Immunofluorescent MUC5B levels in SARS-CoV-2 ratioed to mock HBE culture levels at 3 and 14 dpi. **(B)** Ion transport genes. **(Bi)** Heatmap depicting pattern of ion transport genes in mock vs. SARS-CoV-2-infected HBE cultures with time post-infection. **(Bii)** Box plot depicting mean ion transport gene expression over time. **(C)** Box plot depicting mean antioxidant proteins collected from culture apical surfaces over time post-infection. **(D)** Antimicrobial defense molecules. **(Di)** Box plot depicting SCGB1A1 protein levels with time post infection. **(Dii)** Box plots depicting mean Reactome antimicrobial proteins with time post-infection. Statistics conducted and symbols as described in **Figure 3** legend.

990
Figure 8. SARS-CoV-2 infectivity and HBE culture host responses as a function of sex. (A) Box plots
depicting mean titers in SARS-CoV-2 infected HBE cultures from 0-3 dpi colored by sex. **(Aii)** Slopes of
mean titers in each sex for dpi 0-3 (slope = 1.77 for females and 1.40 for males). The p-value of the
difference between the slopes (-0.37) is 0.0226. The shaded areas represent the 95% confidence intervals.
(Aiii/iv) As for (Ai-iii) expect representing titer data for dpi 3, 7, and 14. **(B)** Venn diagram representing
differentially expressed genes (DEGs) between sexes from analyses of mock HBE cultures at the dpi
indicated. Numbers in parentheses represent the total number of DEGs in each group. DEGs represented
are filtered at adjusted P-value of <0.05 and absolute log2 fold-change >1 with an average expression >0
(log2; or roughly TMP>1). **(C)** Schematic representation of DEGs between the two sexes at the times and
treatments indicated (m=mock; v=virus). Coloring represents the location of the DEGs on the
chromosomes where Auto=all autosomes. DEGs represented are filtered as for (B). **(D)** Simplified
heatmap of differentially expressed pathways from Reactome + custom annotation set for female vs. male
in mock infected HBE cultures. Red pathways are upregulated in females compared to males; blue
pathways are upregulated in males compared to females. NES=normalized enrichment score. **(E)**
Replication cohort (Protocol 2). **(Ei)** Box plots depicting mean titers in SARS-CoV-2 infected HBE
cultures from 0-3 dpi colored by sex Protocol 2. **(Eii)** Combined titer data for Protocols 1-2. No
significant difference between sexes were found for any timepoint measured.
1008

1009

Figure 9. SARS-CoV-2 infectivity and HBE culture host responses as a function of age. (A) Box
plots depicting mean titers in SARS-CoV-2 infected cultures separated into age groups. No significant
differences were found among ages at any timepoint measured. **(Ai)** Titers 1-3 dpi; **(Aii)** titers 3-14 dpi.
(Aiii) Slopes of viral titers from 3, 7, and 14 dpi as a function of age. M = mature; Y = young; E = elderly.
Shaded areas represent the 95% confidence intervals. **(B)** PCA of global bulk RNAseq transcriptomics
colored by age group. Ellipses are drawn at 95% level assuming normal distributions of samples per
group. **(C)** Pathways selected from bulk RNAseq data by the Reactome + custom pathway annotation
describing differentially regulated pathways in mock treated cultures between the age groups shown at the
dpi indicated. **(D)** Selected differentially regulated pathways in virus-treated samples between the age
groups shown at the indicated. For (C-D), NES=normalized enrichment score. **(E)** Replication Protocol 2
data for titer plotted by age. **(F)** Ridge plots representing **(Fi)** ISGs and **(Fii)** DNA methylation signatures
between age groups and times dpi.

1022

1023

Figure 10. Relationship of failed repair to COVID-19 disease. A repair index score as a function of **(A)** viral gene expression (TPM) at 3 dpi, **(B)** peak LDHB protein in secretions at 7 dpi, **(C)** sex, and **(D)** age. All comparisons depict the repair index at 14 dpi. **(E-G)** Failed repair genes are enriched in GSEA analyses for **(E)** a reported autopsy (~ 30 d post-SARS-CoV-2 symptom initiation) with early pulmonary fibrotic histologic changes (46); **(F)** GeoMX spatial transcriptomics studies of conducting airway epithelia of five subjects 6-12 mo post-initiation of SARS-CoV-2 symptoms who exhibited persistent CT abnormalities and required VATS biopsies, again with fibrotic changes evident on histology; and **(G)** transbronchoscopic epithelial biopsies of subjects exhibiting a long pulmonary COVID phenotype that manifests as chronic cough, sputum production, and chest congestion persistently for ~ 18 mo post-SARS-CoV-2 infection vs. subjects who resolved symptoms post-SARS-CoV-2 (46). **(H)** Relationship between ISGs and viral TPM at 14 dpi (slope=0.68 SE 0.14, p<0.0001). **(I)** Selected pathways over-represented (enriched) in failed repair gene set. Shaded areas in A, B, and H represent the 95% confidence intervals.

1037